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ABSTRACT
Prostate cancer predisposition has been extensively investigated in European 
populations, but there have been few studies of other ethnic groups. To investigate 
prostate cancer susceptibility in the under-investigated Chinese population, we 
performed single-nucleotide polymorphism (SNP) array analysis on a cohort of 
Chinese cases and controls and then meta-analysis with data from the existing 
Chinese prostate cancer genome-wide association study (GWAS). Genotyping 
211,155 SNPs in 495 cases and 640 controls of Chinese ancestry identified several 
new suggestive Chinese prostate cancer predisposition loci. However, none of them 
reached genome-wide significance level either by meta-analysis or replication study. 
The meta-analysis with the Chinese GWAS data revealed that four 8q24 loci are the 
main contributors to Chinese prostate cancer risk and the risk alleles from three of 
them exist at much higher frequencies in Chinese than European populations. We 
also found that several predisposition loci reported in Western populations have 
different effect on Chinese men. Therefore, this first extensive single-nucleotide 
polymorphism study of Chinese prostate cancer in comparison with European 
population indicates that four loci on 8q24 contribute to a great risk of prostate 
cancer in a considerable large proportion of Chinese men. Based on those four loci, 
the top 10% of the population have six- or two-fold prostate cancer risk compared 
with men of the bottom 10% or median risk respectively, which may facilitate the 
design of prostate cancer genetic risk screening and prevention in Chinese men. 
These findings also provide additional insights into the etiology and pathogenesis 
of prostate cancer.
INTRODUCTION
The incidence and mortality rates of prostate cancer 
vary dramatically among countries with 24-fold and 10-
fold difference, respectively, in 2008 [1]. While it is the 
most common male cancer in most of America, Oceania, 
western and northern European countries, its incidence in 
China is much lower. Despite a rapid increase of prostate 
cancer incidence in China in recent years, the variation 
between China and Western countries is still large. Both 
genetic and environmental factors may contribute to this 
finding, potentially through the induction of different 
genetic changes [2].
Previous prostate cancer predisposition studies, 
particularly genome-wide association studies (GWAS), 
have been mainly performed in populations from European 
ancestors [3–20]. While certain loci may contribute to 
prostate cancer in multiple ethnic populations, population 
differences have been previously demonstrated [3, 16, 18, 
21]. Only one GWAS has been performed in the Chinese 
population [18]. In association with the Prostate Cancer 
Association Group to Investigate Cancer Associated 
Alterations in the Genome (PRACTICAL) consortium 
for prostate cancer predisposition study [6, 8, 15], we 
investigated genetic predisposition to prostate cancer in 
men of Han Chinese ancestry using the custom Illumina 
single-nucleotide polymorphism (SNP) array (iCOGS) [8]. 
Meta-analysis with the Chinese GWAS data [18] revealed 
few suggestive loci. Importantly, we found that four loci 
on 8q24 contribute in a large proportion of Chinese men to 
a considerable risk of prostate cancer, which are different 
in the European population.
RESULTS
Genotyping and analysis
We genotyped 495 prostate cancer cases and 640 
age matched non-cancer male controls (Supplementary 
Table S1) using the iCOGS SNP array [8]. No population 
outliers were identified in population structure analysis 
(Supplementary Figure S1) and 170,264 SNPs in 455 
cases and 614 controls were retained for association 
analysis after systematic quality control. The quantile-
quantile plot based on the association results showed 
minimal evidence of inflation (λ=1.04)(Supplementary 
Figure S2). We found eight SNPs independently 
associated with prostate cancer with P<1×10-4 and r2<0.5 
for linkage disequilibrium (LD) (Table 1). Five of them 
have not been reported as associated with prostate cancer 
risk (Supplementary Figure S3) and the other three, all 
located at 8q24 regions, were previously reported (Table 
1). However, the haplotype pattern observed in our 
genotype data suggests that SNP rs7463708, which is 
located within the previously reported 8q24 predisposition 
loci region 2, is potentially independent from region 2 
for prostate cancer predisposition in Chinese population 
(Figure 1) and demonstrates the strongest association with 
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prostate cancer risk at the array stage. For additionally 
exploratory purposes, we performed a stepwise logistic 
regression analysis using the three 8q24 SNPs (P<1×10-4 
and r2<0.5 for LD) and all previously reported prostate 
cancer predisposition loci located in 8q24 region. The 
multivariate analysis performed using the stepwise-
selected model showed that rs7463708 exhibits 
independent association with Chinese prostate cancer 
(Supplementary Table S2). This adds further evidence 
that rs7463708 represents loci associated with prostate 
cancer in Chinese population independent from other 
8q24 predisposition SNPs.
Population genetic risk similarities and 
differences
To explore the population genetic risk differences we 
checked our data for previously reported prostate cancer 
predisposition loci in European and Japanese populations. 
We found suggestive association (P<0.05) in only nine 
Table 1: SNPs independently associated with prostate cancer risk with P<1×10-4 at the array genotyping stage of 
Chinese samples
    MAF   Previously 
reported SNP Locationa Allelesb Study Case Control OR (95% CI)c PGCd
rs12567052 1q32.1 (200494416) G/A Chinese
e 0.241 0.321 0.67 (0.55-0.81) 5.89×10-5 No
  G/A Europeanf 0.404 0.399 1.02 (1.00-1.05) 1.69×10-2  
rs10235505 7p21.3 (7441152) G/A Chinese
e 0.347 0.266 1.45 (1.20-1.74) 9.09×10-5 No
  G/A Europeanf 0.247 0.244 1.02 (0.99-1.05) 2.30×10-1  
rs1532980 8p23.1 (9848617) T/C Chinese
e 0.428 0.486 0.70 (0.59-0.84) 8.65×10-5 No
  T/C Europeanf 0.252 0.248 1.02 (0.99-1.05) 2.42×10-1  
rs7463708 8q24.21 (128104055) T/G Chinese
e 0.232 0.331 0.60 (0.49-0.74) 7.00×10-7 ?
  G/T Europeanf 0.280 0.260 1.11 (1.07-1.14) 6.87×10-10  
rs7013255 8q24.21 (128130487) T/G Chinese
e 0.340 0.257 1.46 (1.21-1.76) 5.90×10-5 Yes
  T/G Europeanf 0.053 0.032 1.69 (1.58-1.81) 4.17×10-48  
rs13255059 8q24.21 (128530616) G/A Chinese
e 0.206 0.130 1.74 (1.37-2.20) 4.22×10-6 Yes
  G/A Europeanf 0.150 0.109 1.45 (1.39-1.50) 5.24×10-69  
rs10746597 9q21.31 (82344077) A/G Chinese
e 0.354 0.271 1.52 (1.25-1.85) 2.58×10-05 No
  A/G Europeanf 0.415 0.416 0.99 (0.97-1.02) 7.04×10-1  
rs1335214 9q33.2 (122847182) G/C Chinese
e 0.467 0.376 1.46 (1.22-1.74) 2.82×10-05 No
  C/G Europeanf 0.420 0.421 0.99 (0.97-1.02) 8.16×10-1  
Abbreviations: MAF, minor allele frequency.
aChromosomal and physical (in bracket) locations based on NCBI Human Genome Build 37.
bMajor/minor allele.
cAllelic OR with 95% CI for the minor allele in association with prostate cancer risk.
dPGC values in Chinese study indicate λ-corrected P values.
eiCOGS study on Chinese population.
fPRACTICAL iCOGS study on European population.
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of the 91 (10%) prostate cancer risk SNPs previously 
identified in European descendants and successfully 
measured by iCOGS array or imputed. Three of them 
are located at 8q24 (Supplementary Table S3). Whereas 
three of the seven (43%) predisposition SNPs initially 
identified in Japanese population showed association with 
prostate cancer (P<0.05) in our data (Supplementary Table 
S3 and Supplementary Figure S4). We further estimated 
the heterogeneity for these predisposition loci between 
European and Chinese descendants using our Chinese 
and the PRACTICAL European array data. 24 of 96 
showed opposite odds ratio (OR) direction and seven loci 
demonstrated significant differences (Phet<0.05) in prostate 
cancer association between Chinese and European data 
sets (Supplementary Table S3 and Supplementary Figure 
S5). For the remaining previously reported prostate cancer 
predisposition loci, no evidence for significant difference 
between those two populations was found.
Chinese prostate cancer predisposition  
meta-analysis
To increase the statistical power and reduce potential 
false-positive findings we performed meta-analysis with 
the Chinese GWAS data [18] using SNPs associated 
with prostate cancer at P<0.001 in our iCOGS array data 
(Supplementary Table S4). After combining the results from 
both studies using fixed-effect model, nine loci reached an 
association with prostate cancer at P<1×10-3 (Table 2 and 
Supplementary Table S4). Two previously reported loci 
at 8q24 (region 1 and 2) reached the GWAS significance 
(P<5×10-8) and one (region 3) reached association 
significance of P=2.5×10-7. In addition, SNP rs1456315 
closely linked with rs7463708 (r2=0.83), which is absent in 
Chinese GWAS data, demonstrated the strongest evidence 
of prostate cancer association in Chinese men (Table 2 and 
Supplementary Table S4). This is consistent with the Chinese 
Figure 1: Regional association plot and LD map around SNP rs7463708. Top and bottom panels illustrate regional associations 
and LD map, respectively, around SNP rs7463708 potentially independently associated with prostate cancer. SNPs genotyped in this study, 
imputed on the basis of the 1000 Genomes Project data (Phase 1 integrated data version 3, March 2012) and rs16901979 (P value based on 
published data) associated with prostate cancer are indicated by circles, diamonds and square, respectively. Each point size is proportional 
to sample size. Symbol colors represent the LD of rs7463708 (purple circle) with nearby SNPs. The legend for LD measure (r2) is on the top 
left corner of the plot. The left Y-axis illustrates the –log10 association P values of SNPs and the Y-axis on the right shows the recombination 
rate estimated from the 1000 Genomes Project using Chinese and Japanese population data. The LD map is based on r2 values in CHB (Han 
Chinese in Beijing, China) and JPT (Japanese in Tokyo, Japan) samples from the 1000 Genomes Project.
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GWAS study identifying rs1456315 as the only SNP with a 
genome-wide significance level at the GWAS stage [18]. In 
this Chinese and a previous Japanese study [16], rs1456315 
was considered to be within the same LD as the previously 
reported 8q24 region 2 identified in populations of European 
ancestry. However, the weak linkage (r2=0.14) between 
rs1456315 and region 2 prostate cancer risk susceptibility 
locus (rs16901979) (Figure 1 and 2D), together with strong 
association of rs1456315 (OR=0.66, 95% confidence 
intervals (CI)=0.52-0.82, P=2.81×10-4) remaining after 
conditioning on the effects of all the other predisposition loci 
at 8q24 region using iCOGS array data, suggests that these 
two loci are independently associated with Chinese prostate 
cancer. Apart from SNPs at 8q24 region, no other loci were 
associated with prostate cancer with P<1×10-4 (Table 2 and 
Supplementary Table S4).
Table 2: Results summary of prostate cancer susceptibility loci with P<1×10-3 in meta-analysis of Chinese iCOGS 
and Chinese GWAS data
SNPa Location Allelesb Reported loci Study OR (95% CI)c P
rs4539815 2q12 T/C No iCOGS 1.42 (1.17-1.74) 5.50×10-4
    GWAS 1.14 (1.00-1.31) 6.45×10-2
    Combined 1.22 (1.09-1.37) 4.43×10-4
rs12622816 2q31 G/A rs12621278 iCOGS 0.72 (0.59-0.87) 8.92×10-4
    GWAS 0.86 (0.76-0.98) 1.94×10-2
    Combined 0.82 (0.73-0.91) 1.56×10-4
rs13319291 3q22 G/A No iCOGS 0.71 (0.59-0.84) 1.37×10-4
    GWAS 0.90 (0.80-1.02) 8.40×10-2
    Combined 0.83 (0.76-0.92) 3.64×10-4
rs1456315 8q24 (region 2) A/G No iCOGS 0.61 (0.50-0.75) 3.78×10-6
    GWAS 0.61 (0.53-0.70) 2.76×10-13
    Combined 0.61 (0.55-0.68) 7.93×10-18
rs7013255 8q24 (region 2) A/G rs16901979 iCOGS 1.46 (1.22-1.76) 5.90×10-5
    GWAS 1.41 (1.24-1.60) 1.07×10-7
    Combined 1.43 (1.29-1.58) 2.28×10-11
rs12682374 8q24 (region 3) G/C rs6983267 iCOGS 1.36 (1.14-1.61) 5.56×10-4
    GWAS 1.26 (1.12-1.42) 1.01×10-4
    Combined 1.29 (1.17-1.42) 2.49×10-7
rs7824868 8q24 (region 1) C/T rs4242382 iCOGS 1.73 (1.37-2.18) 4.61×10-6
    GWAS 1.54 (1.32-1.80) 5.14×10-8
    Combined 1.60 (1.40-1.82) 2.02×10-12
rs6598099 11q13 C/T No iCOGS 1.44 (1.18-1.77) 3.97×10-4
    GWAS 1.12 (0.98-1.28) 8.53×10-2
    Combined 1.21 (1.08-1.35) 8.18×10-4
rs1893384 18q11 C/A No iCOGS 2.55 (1.50-4.31) 5.20×10-4
    GWAS 1.37 (0.94-1.99) 9.95×10-2
    Combined 1.69 (1.24-2.29) 7.71×10-4
Abbreviation: GWAS, genome-wide association study.
aSNP with the strongest evidence of prostate cancer association in Chinese men accordingly to meta-analysis of Chinese 
iCOGS and Chinese GWAS data sets.
bMajor/minor allele.
cOR with 95% CI for the minor allele in association with prostate cancer risk.
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We checked the risk allele frequencies of these 8q24 
SNPs in Chinese, Japanese and European populations. 
Surprisingly, we found that apart from 8q24 region 3, 
the risk allele frequencies of all SNPs are much higher in 
Chinese than European population and, for rs1456315 and 
rs13254738, the risk alleles are the major alleles in Chinese 
population but minor alleles in European population. The 
risk allele frequencies for many of these 8q24 SNPs are 
also higher in Chinese than Japanese population, although 
the differences are less apparent. Only for some SNPs 
at 8q24 region 1, the risk allele frequencies are slightly 
lower in Chinese than Japanese population (Figure 2A). 
This study also benefits from the direct comparison of the 
combined Chinese array data with PRACTICAL European 
population data of 25,074 cases and 24,272 controls. Apart 
from SNPs between rs1073997 and rs16901984 on 8q24 
region 2 (Figure 2D), where the risk allele frequencies are 
very low (<5%) in European population, all the remaining 
risk SNPs had higher ORs in Chinese than the European 
men (Figure 2B). Interestingly, the two SNPs (rs1456315 
and rs13254738) demonstrating the highest association 
with prostate cancer in Chinese population (P=7.93×10-
18 and 2.22×10-16 respectively) are not associated with 
prostate cancer at the GWAS level (P<5×10-8) in European 
men (Figure 2C). Due to the high frequency of those risk 
alleles, the four 8q24 SNPs (rs1456315, rs16901979, 
rs6983267 and rs4242382) independently associated with 
Chinese prostate cancer coexist in a considerable large 
proportion of Chinese men, i.e. 6.5% subjects have six 
or more of these risk alleles. Based on these four loci, 
the prostate cancer risk for men in the top 10% of the 
polygenic risk score (PRS) distribution was 5.91 (95% CI, 
2.68-13.04) fold compared with men in the bottom 10%, 
and around two-fold (1.96, 95% CI, 1.36-2.82) compared 
with the median risk (Supplementary Table S5). When we 
looked only at the top 5% of the population, the prostate 
cancer risk was 8.89 (95% CI, 3.46-22.83) fold compared 
with men in the bottom 5%, and 2.32 (95% CI, 1.55-3.49) 
fold compared with the median risk.
Replication of unreported SNPs
As none of the new suggestive loci (P<0.001) 
from our iCOGs analysis were supported by the Chinese 
GWAS data, we attempted to replicate the five association 
signals passing nominal significance P<1×10−4 at the 
iCOGS stage (rs12567052, rs10235505, rs1532980, 
rs10746597 and rs1335214) using the TaqManTM method 
in additional cohort of 1,940 cases and 2,820 controls of 
Han Chinese ancestry. Association analysis using the same 
approach as in the iCOGS genotyping stage confirmed 
two SNPs, rs12567052 at 1q32.1 (P=1.9×10−4) and 
rs10235505 at 7p21.3 (P=9.9×10−4), to have significant 
association with prostate cancer, while the other three 
were either not significantly associated (P>0.05) or 
demonstrated opposite effect to that observed at the array 
stage (Supplementary Table S6). After combining the 
results from both stages using a meta-analysis assuming 
fixed-effect, the rs12567052[A] allele at 1q32.1 was 
associated with an OR of 0.79 for prostate cancer risk 
(95% CI=0.72-0.86, P=2.41×10−7) and the rs10235505[A] 
allele at 7p21.3 was associated with an OR of 1.22 (95% 
CI=1.12-1.33, P=2.4×10-6) (Supplementary Table S6). 
For both SNPs, the allele frequency differed considerably 
between the populations of European and Chinese (Table 
1). In the PRACTICAL iCOGS cohort, which mainly 
contains European descendants [8], the rs12567052[A] 
putative protective allele in Chinese population showed 
significantly higher frequency in cases than controls 
(P=0.017). The rs10235505 did not show association with 
prostate cancer risk (P=0.23) (Table 1).
DISCUSSION
While more than 100 prostate cancer predisposition 
loci have been identified [3-20, 22, 23], the majority are 
from European patients. Identifying the predisposition loci 
in Asian populations, where prostate cancer incidence is 
relatively low, may not only help to prevent an increase 
of incidence rate in these populations, but also contribute 
to our understanding of the molecular and genetic 
mechanisms underlying prostate carcinogenesis by 
evaluating population differences.
In this study we identified a number of suggestive 
prostate cancer-associated genetic loci in Chinese Han 
population using the custom iCOGS array. Two of them, 
rs12567052 and rs10235505, remained to be associated at 
the replication stage, but none reached the genome-wide 
level significance when combined all the data. Further 
studies with much larger sample size are required to 
determine if rs12567052 and rs10235505 are associated 
with Chinese prostate cancer risk. The SNP with the 
strongest association at the array stage was rs7463708 at 
8q24 (OR=0.60, 95% CI=0.49-0.74, P=7.00×10-7), which 
is consistent with the Chinese GWAS study identifying 
rs1456315, a SNP in strong linkage with rs7463708, as 
the only SNP with a genome-wide significance level at 
the GWAS stage [18]. While this SNP is located within 
previously reported prostate cancer predisposition loci 
8q24 region 2 identified in populations of European 
ancestry, the haplotype pattern observed in our genotype 
data and stepwise logistic regression analysis suggest that 
these two loci are independently associated with prostate 
cancer in Chinese population.
By comparing our data with prostate cancer 
predisposition loci reported in European and Japanese 
populations [4, 6-17, 20, 24-29], we found that many 
prostate cancer predisposition loci identified in European 
population are not associated with prostate cancer in 
Chinese men. Clearly the sample size of our study is 
relatively small, hence the statistical power is limited and 
with increased sample size more reported predisposition 
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Figure 2: The risk allele frequency, OR and P value plots at the four 8q24 prostate cancer-associated loci in Chinese, 
Japanese and European descendants. A. Risk allele frequency, B. OR and C. P value plots of SNPs with P<1×10-4 in meta-analysis 
results of Chinese data. D. LD map of 8q24 region based on r2 values computed using iCOGS Chinese genotyping data. Index SNPs are 
highlighted in grey on the LD plot. The independently associated SNP rs1456315 in Chinese iCOGS data is highlighted in blue. Previously 
reported prostate cancer-associated regions 1, 2 and 3 are indicated below the LD map. The vertical dashed lines distinguish the four 8q24 
loci independently associated with Chinese prostate cancer accordingly to Chinese iCOGS data. iCOGS: iCOGS array data from Chinese 
ancestors; PRACTICAL: iCOGS array data from European ancestors; 1000 GP: 1000 Genome Project data; GWAS: Chinese GWAS data.
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loci to the European men are likely to be confirmed in 
the Chinese population. However, the much greater 
proportion of predisposition loci identified in Japanese 
population compared to those identified in European 
populations, which demonstrated an association (P<0.05) 
in our Chinese cohort, suggests that these two Eastern 
Asian populations have more similar genetic risk to 
prostate cancer than European descent. Moreover, we 
observed prominent difference in allele frequency in the 
8q24 loci and several loci reported in Western populations 
that have significantly different effect on Chinese men, 
demonstrating that certain population difference in 
prostate cancer predisposition exists. However, while 
we identified differences between Chinese and European 
populations for certain previously reported prostate 
cancer predisposition loci, the majority of them did not 
demonstrate significant heterogeneity between data sets 
derived from Chinese and European descendants. This 
is convergent with the presumption that many genetic 
predisposition loci may contribute to prostate cancer in 
multiple ethnic populations.
The current sample size of microarray data for 
Chinese prostate cancer predisposition study is still 
limited. Therefore, susceptibility loci with very low 
penetrance may not be detected due to insufficient 
statistical power. Further Chinese studies with larger 
cohort of samples are required to comprehensively 
characterize the genetic predisposition of prostate cancer 
in Chinese men. However, the much greater significance 
of prostate cancer association at these four 8q24 SNPs 
compared with other SNPs in the Chinese array data sets 
indicate that other loci potentially to be confirmed or 
identified in Chinese population may have much smaller 
contribution to prostate cancer risk in Chinese population. 
As a large proportion (around 6.5%) of Chinese men 
carry six or more of these 8q24 risk alleles and the top 
10% of the population have six- and two-fold prostate 
cancer risk compared with men of the bottom 10% and 
median risk respectively, these four 8q24 SNPs may be 
implemented in a simple prostate cancer genetic risk 
screening kit to detect these high-risk Chinese men for 
individualized cancer prevention. In addition to individual 
genetic risk assessment for cancer prevention, SNP-based 
prediction model for prostate cancer diagnosis has also 
been developed [30, 31]. In a previously reported 24 
SNP-based genetic score for prostate cancer diagnosis 
prediction in Chinese population, three of the four SNPs 
in our study, rs16901979, rs6983267 and rs1447295, have 
been genotyped. We compared the performance of our 
three-SNP combination in comparison to the 24 SNPs and 
the area under the curve (AUC) for our three SNPs was 
0.646 and the AUC for the 24 SNPs was 0.658. Although 
the 24 SNPs performed slightly better than the three SNPs, 
the cancer prediction value is similar. It is possible that 
including the 4th SNP, rs1456315, which demonstrated the 
strongest signal in the Chinese iCOGS and GWAS, could 
further improve the AUC, suggesting these four 8q24 
SNPs may also be useful for diagnosis prediction. This 
genetic score data also support our observation that the 
other SNPs have limited contribution to prostate cancer 
risk in Chinese men.
While those findings suggest that Chinese 
population has fewer genetic risk loci for prostate cancer 
than European population, which is consistent with the 
prostate cancer incidence disparity between these two 
populations, it is surprising that the risk alleles are more 
frequent and ORs are greater at these four 8q24 loci in 
Chinese than European descendants. Our findings suggest 
that Chinese population either generally has a lower 
genetic risk or is better protected by healthy diet than 
European population, resulting in much lower incidence 
and mortality of prostate cancer. If the former is true, it 
means that the recent rapid increase in Chinese prostate 
cancer incidence will peak soon and won’t ever achieve 
European levels. However, if the latter is the case, with 
dietary change and increased population, prostate cancer 
will become a common cancer in China.
In summary, while we did not identify new prostate 
cancer predisposition loci at genome-wide significance 
level in Chinese population using our SNP array data, 
meta-analysis and replication study, the meta-analysis with 
Chinese GWAS showed that four 8q24 loci increase the 
risk of prostate cancer considerably in a large proportion 
of Chinese men. These four 8q24 loci bear great potential 
for designing a simple prostate cancer risk screening kit to 
identify risk individuals in the large Chinese population. 
We also identified differences between Chinese and 
European populations for certain previously reported 
prostate cancer predisposition loci. These findings will 
help to understand the predisposition and molecular 
mechanisms of prostate carcinogenesis and improve 
cancer prevention.
MATERIALS AND METHODS
Study design
In this study 211,155 SNPs were genotyped in 495 
cases and 640 age-matched non-cancer male controls 
from the Han Chinese population using iCOGS array [8] 
at Beijing Genome Institute. The array was designed by 
the international consortium, COGS, to detect genetic 
variants related to prostate, breast and ovarian cancers. 
The replication of nominally associated SNPs within 
unreported loci was performed in additional 1,940 cases 
and 2,820 controls. Demographic and clinical features of 
subjects for the prostate cancer predisposition study are 
summarized in Supplementary Table S1. These male Han 
Chinese subjects were recruited from several regions of 
China (south, southeast, southwest, middle and northeast) 
by members of the Chinese Prostate Cancer Genetic 
and Environmental Correlation Study (CHIPGECS) 
Oncotarget21401www.impactjournals.com/oncotarget
collaborative group. The cases were hospital based with 
pathological diagnosis of primary prostate cancer. Similar 
numbers of cancer-free controls and cases were recruited 
from the community or hospital subjects undergoing 
routine physical examination in each recruitment region 
in China. Controls are all males with comparable ages to 
the cases, particularly for the first stage conducted with 
iCOGS array. Blood samples were obtained with informed 
consent and the study was approved by the Institutional 
Ethical Committee of each participating institution. The 
Chinese GWAS [18] data used for meta-analysis contained 
1,417 cases and 1,008 cancer-free male controls from 
the Han Chinese population. The GWAS study subjects 
selection and genotype data quality control methods were 
previously described [18].
Genotype quality control
Systematic quality control steps were conducted on 
the raw iCOGS genotyping data resulting in the exclusion 
of 15 samples with an overall genotyping success rate 
less than 95%, four samples with high B allele frequency 
(BAF) variance, ten samples predicted as female based 
on X chromosome specific inbreeding coefficient (F) 
less than 0.2, and two samples with low heterozygosity 
(F>0.1). Additional 35 samples identified as duplicates 
or second-degree relatives were excluded on the basis 
of identity-by-descent analysis performed using PLINK 
(v1.07) [32].
Ancestry and population stratification were 
determined by principal component analysis. The principal 
components were calculated for a subset of 66,878 
uncorrelated (r2<0.5) autosomal SNPs that passed quality 
control and were present on both the iCOGS array and in 
HapMap 3 data from four reference populations including 
CEU (Utah residents with Northern and Western European 
ancestry), CHB (Han Chinese in Beijing, China), JPT 
(Japanese in Tokyo, Japan) and YRI (Yoruba in Ibadan, 
Nigeria)(Supplementary Figure S1A). Subsequently, 
principal components were calculated for a set of 71,591 
uncorrelated autosomal markers present on the iCOGS 
array alone (Supplementary Figure S1B).
The exclusion criteria for SNPs were genotyping call 
rate less than 95% (3,174 SNPs), minor allele frequency 
(MAF) less than 1% (37,920 SNPs) and genotype frequency 
that deviated from expected Hardy-Weinberg equilibrium 
among control samples (P<1×10-4) (1,039 SNPs).
Statistical analyses
The association between each SNP and the disease 
phenotype was estimated by per-allele OR and 95% CI 
using unconditional logistic regression implemented in 
PLINK, assuming an additive genetic model. A genomic 
control (GC) method was applied to adjust the P values 
for unknown genetic heterogeneity. Ungenotyped SNPs 
within 100kb flanking regions on each side of associated 
SNPs (P<1×10-4) were imputed with IMPUTE2 (version 
2.3.0) software[33] using 1000 Genomes Project data 
(Phase 1 integrated data version 3, March 2012) from 
Chinese and Japanese populations as reference haplotype 
maps. A pre-phasing technique was applied to SNP array 
data to produce best-guess haplotypes and speed up the 
imputation process[34]. A posterior probability greater 
than 0.9 was applied to call imputed genotypes. Haploview 
software (v4.2)[35] was used to determine pair-wise LD 
structure across interrogated genomic regions. CLUMP 
analysis with PLINK was performed to identify SNPs 
independently associated with the disease phenotype. 
Akaike information criterion (AIC) was used for stepwise 
logistic regression model selection. Conditional and 
stepwise logistic regression analyses were performed in R.
Results obtained in independent genotyping 
analysis were combined with fixed-effect meta-analysis 
implemented in PLINK. The heterogeneity between 
studies was tested with Cochran’s Q test statistic. Results 
that obtained P value less than 5.0×10-8 were considered 
statistically significant at the genome-wide level.
The different prostate cancer risk strata were defined 
by PRS constructed from the summed genotypes weighted 
by the estimated per-allele log-ORs obtained in meta-
analysis for each of the four 8q24 loci (Supplementary 
Table S7)[36].
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